BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hofmann WP, Zeuzem S. A new standard of care for the treatment of chronic HCV infection. Nat Rev Gastroenterol Hepatol 2011;8:257-64. [PMID: 21468124 DOI: 10.1038/nrgastro.2011.49] [Cited by in Crossref: 92] [Cited by in F6Publishing: 93] [Article Influence: 8.4] [Reference Citation Analysis]
Number Citing Articles
1 Surah S, Kieran J, O'Dea S, Shiel C, Raffee S, Mulcahy F, Keenan E, Lyons F. Use of the Alcohol Use Disorders Identification Test (AUDIT) to determine the prevalence of alcohol misuse among HIV-infected individuals. Int J STD AIDS 2013;24:517-21. [PMID: 23970765 DOI: 10.1177/0956462412473885] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
2 Bota S, Sporea I, Şirli R, Neghină AM, Popescu A, Străin M. Role of interleukin-28B polymorphism as a predictor of sustained virological response in patients with chronic hepatitis C treated with triple therapy: a systematic review and meta-analysis. Clin Drug Investig 2013;33:325-31. [PMID: 23532802 DOI: 10.1007/s40261-013-0074-0] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 2.7] [Reference Citation Analysis]
3 Chen LP, Zhao J, Du Y, Han YF, Su T, Zhang HW, Cao GW. Antiviral treatment to prevent chronic hepatitis B or C-related hepatocellular carcinoma. World J Virol 2012; 1(6): 174-183 [PMID: 24175223 DOI: 10.5501/wjv.v1.i6.174] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
4 Kwong AD, Kauffman RS, Hurter P, Mueller P. Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus. Nat Biotechnol 2011;29:993-1003. [PMID: 22068541 DOI: 10.1038/nbt.2020] [Cited by in Crossref: 203] [Cited by in F6Publishing: 178] [Article Influence: 18.5] [Reference Citation Analysis]
5 Safi SZ, Waheed Y, Sadat J, Solat-Ul-Islam, Salahuddin S, Saeed U, Ashraf M. Molecular study of HCV detection, genotypes and their routes of transmission in North West Frontier Province, Pakistan. Asian Pac J Trop Biomed 2012;2:532-6. [PMID: 23569965 DOI: 10.1016/S2221-1691(12)60091-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 2.1] [Reference Citation Analysis]
6 Abdel Karim SE, Youssef YH, Abdel-Halim M, Frakolaki E, Vassilaki N, Zoidis G, Ahmed NS, Abadi AH. Symmetric benzidine derivatives as anti-HCV agents: Insight into the nature, stereochemistry of the capping amino acid and the size of the terminal capping carbamates. Bioorg Chem 2020;102:104089. [PMID: 32717691 DOI: 10.1016/j.bioorg.2020.104089] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Paeshuyse J, Dallmeier K, Neyts J. Ribavirin for the treatment of chronic hepatitis C virus infection: a review of the proposed mechanisms of action. Current Opinion in Virology 2011;1:590-8. [DOI: 10.1016/j.coviro.2011.10.030] [Cited by in Crossref: 86] [Cited by in F6Publishing: 79] [Article Influence: 7.8] [Reference Citation Analysis]
8 Pyne MT, Hillyard DR. Evaluation of the Roche COBAS AmpliPrep/COBAS TaqMan HCV Test. Diagnostic Microbiology and Infectious Disease 2013;77:25-30. [DOI: 10.1016/j.diagmicrobio.2013.05.012] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
9 Fiorucci G, Chiantore MV, Mangino G, Romeo G. MicroRNAs in virus-induced tumorigenesis and IFN system. Cytokine Growth Factor Rev 2015;26:183-94. [PMID: 25466647 DOI: 10.1016/j.cytogfr.2014.11.002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
10 Urban T, Charlton MR, Goldstein DB. Introduction to the genetics and biology of interleukin-28B. Hepatology 2012;56:361-6. [PMID: 22511448 DOI: 10.1002/hep.25794] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
11 Jiang J, Cun W, Wu X, Shi Q, Tang H, Luo G. Hepatitis C virus attachment mediated by apolipoprotein E binding to cell surface heparan sulfate. J Virol 2012;86:7256-67. [PMID: 22532692 DOI: 10.1128/JVI.07222-11] [Cited by in Crossref: 122] [Cited by in F6Publishing: 83] [Article Influence: 12.2] [Reference Citation Analysis]
12 Macarthur KL, Smolic R, Smolic MV, Wu CH, Wu GY. Update on the Development of Anti-Viral Agents Against Hepatitis C. J Clin Transl Hepatol 2013;1:9-21. [PMID: 26357602 DOI: 10.14218/JCTH.2013.007XX] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
13 Dill MT, Makowska Z, Duong FHT, Merkofer F, Filipowicz M, Baumert TF, Tornillo L, Terracciano L, Heim MH. Interferon-γ-stimulated genes, but not USP18, are expressed in livers of patients with acute hepatitis C. Gastroenterology 2012;143:777-786.e6. [PMID: 22677194 DOI: 10.1053/j.gastro.2012.05.044] [Cited by in Crossref: 46] [Cited by in F6Publishing: 49] [Article Influence: 4.6] [Reference Citation Analysis]
14 Dore GJ, Matthews GV, Rockstroh J. Future of hepatitis C therapy: development of direct-acting antivirals. Curr Opin HIV AIDS. 2011;6:508-513. [PMID: 21897228 DOI: 10.1097/COH.0b013e32834b87f8] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
15 Hofmann WP, Sarrazin C, Zeuzem S. Current standards in the treatment of chronic hepatitis C. Dtsch Arztebl Int. 2012;109:352-358. [PMID: 22675406 DOI: 10.3238/arztebl.2012.0352] [Cited by in Crossref: 6] [Cited by in F6Publishing: 13] [Article Influence: 0.6] [Reference Citation Analysis]
16 Qu B, Brown RJP. Strategies to Inhibit Hepatitis B Virus at the Transcript Level. Viruses 2021;13:1327. [PMID: 34372533 DOI: 10.3390/v13071327] [Reference Citation Analysis]
17 Berger CT, Kim AY. IL28B polymorphisms as a pretreatment predictor of response to HCV treatment. Infect Dis Clin North Am 2012;26:863-77. [PMID: 23083820 DOI: 10.1016/j.idc.2012.08.010] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
18 Ali A, Aydin C, Gildemeister R, Romano KP, Cao H, Ozen A, Soumana D, Newton A, Petropoulos CJ, Huang W, Schiffer CA. Evaluating the role of macrocycles in the susceptibility of hepatitis C virus NS3/4A protease inhibitors to drug resistance. ACS Chem Biol 2013;8:1469-78. [PMID: 23594083 DOI: 10.1021/cb400100g] [Cited by in Crossref: 45] [Cited by in F6Publishing: 34] [Article Influence: 5.0] [Reference Citation Analysis]
19 Seidenberg A, Rosemann T, Senn O. Patients receiving opioid maintenance treatment in primary care: successful chronic hepatitis C care in a real world setting. BMC Infect Dis. 2013;13:9. [PMID: 23298178 DOI: 10.1186/1471-2334-13-9] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 2.7] [Reference Citation Analysis]
20 Denning J, Cornpropst M, Flach SD, Berrey MM, Symonds WT. Pharmacokinetics, safety, and tolerability of GS-9851, a nucleotide analog polymerase inhibitor for hepatitis C virus, following single ascending doses in healthy subjects. Antimicrob Agents Chemother 2013;57:1201-8. [PMID: 23262999 DOI: 10.1128/AAC.01262-12] [Cited by in Crossref: 30] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
21 Padmanabhan P, Dixit NM. Mathematical model of viral kinetics in vitro estimates the number of E2-CD81 complexes necessary for hepatitis C virus entry. PLoS Comput Biol 2011;7:e1002307. [PMID: 22174670 DOI: 10.1371/journal.pcbi.1002307] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
22 Ahlén G, Frelin L, Brenndörfer ED, Brass A, Weiland O, Chen M, Sällberg M. Containing "The Great Houdini" of viruses: combining direct acting antivirals with the host immune response for the treatment of chronic hepatitis C. Drug Resist Updat 2013;16:60-7. [PMID: 23911647 DOI: 10.1016/j.drup.2013.06.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
23 Kim JW, Park SJ, Lim JH, Yang JW, Shin JC, Lee SW, Suh JW, Hwang SB. Triterpenoid Saponins Isolated from Platycodon grandiflorum Inhibit Hepatitis C Virus Replication. Evid Based Complement Alternat Med 2013;2013:560417. [PMID: 24489585 DOI: 10.1155/2013/560417] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
24 Yoshikawa T, Takata A, Otsuka M, Kishikawa T, Kojima K, Yoshida H, Koike K. Silencing of microRNA-122 enhances interferon-α signaling in the liver through regulating SOCS3 promoter methylation. Sci Rep. 2012;2:637. [PMID: 22957141 DOI: 10.1038/srep00637] [Cited by in Crossref: 56] [Cited by in F6Publishing: 56] [Article Influence: 5.6] [Reference Citation Analysis]
25 Fioravante M, Alegre SM, Marin DM, Lorena SL, Pereira TS, Soares EC. Weight loss and resting energy expenditure in patients with chronic hepatitis C before and during standard treatment. Nutrition 2012;28:630-4. [PMID: 22196981 DOI: 10.1016/j.nut.2011.08.010] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
26 Lenz O, Vijgen L, Berke JM, Cummings MD, Fevery B, Peeters M, De Smedt G, Moreno C, Picchio G. Virologic response and characterisation of HCV genotype 2-6 in patients receiving TMC435 monotherapy (study TMC435-C202). J Hepatol. 2013;58:445-451. [PMID: 23142061 DOI: 10.1016/j.jhep.2012.10.028] [Cited by in Crossref: 66] [Cited by in F6Publishing: 56] [Article Influence: 6.6] [Reference Citation Analysis]
27 Moreno C, Berg T, Tanwandee T, Thongsawat S, Van Vlierberghe H, Zeuzem S, Lenz O, Peeters M, Sekar V, De Smedt G. Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase IIa, open-label study. J Hepatol. 2012;56:1247-1253. [PMID: 22326470 DOI: 10.1016/j.jhep.2011.12.033] [Cited by in Crossref: 82] [Cited by in F6Publishing: 74] [Article Influence: 8.2] [Reference Citation Analysis]
28 López-rodríguez R, Hernández-bartolomé Á, Borque MJ, Rodríguez-muñoz Y, Martín-vílchez S, Trapero-marugán M, García-buey L, Muñoz de Rueda P, Rodrigo L, Vidal-castiñeira JR, Salmerón J, Moreno-otero R, Sanz-cameno P. Polymorphisms in histone deacetylases improve the predictive value of IL-28B for chronic hepatitis C therapy. Genes Immun 2013;14:317-24. [DOI: 10.1038/gene.2013.24] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
29 Madian AG, Wheeler HE, Jones RB, Dolan ME. Relating human genetic variation to variation in drug responses. Trends Genet 2012;28:487-95. [PMID: 22840197 DOI: 10.1016/j.tig.2012.06.008] [Cited by in Crossref: 51] [Cited by in F6Publishing: 39] [Article Influence: 5.1] [Reference Citation Analysis]
30 Fish EN, Platanias LC. Interferon receptor signaling in malignancy: a network of cellular pathways defining biological outcomes. Mol Cancer Res 2014;12:1691-703. [PMID: 25217450 DOI: 10.1158/1541-7786.MCR-14-0450] [Cited by in Crossref: 51] [Cited by in F6Publishing: 27] [Article Influence: 6.4] [Reference Citation Analysis]
31 Malone DF, Falconer K, Weiland O, Sandberg JK. The dynamic relationship between innate immune biomarkers and interferon-based treatment effects and outcome in hepatitis C virus infection is altered by telaprevir. PLoS One 2014;9:e105665. [PMID: 25166593 DOI: 10.1371/journal.pone.0105665] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
32 Horner SM, Gale M Jr. Regulation of hepatic innate immunity by hepatitis C virus. Nat Med 2013;19:879-88. [PMID: 23836238 DOI: 10.1038/nm.3253] [Cited by in Crossref: 208] [Cited by in F6Publishing: 192] [Article Influence: 23.1] [Reference Citation Analysis]
33 de Bruijne J, van de Wetering de Rooij J, van Vliet AA, Zhou XJ, Temam MF, Molles J, Chen J, Pietropaolo K, Sullivan-Bólyai JZ, Mayers D, Reesink HW. First-in-human study of the pharmacokinetics and antiviral activity of IDX375, a novel nonnucleoside hepatitis C virus polymerase inhibitor. Antimicrob Agents Chemother 2012;56:4525-8. [PMID: 22664976 DOI: 10.1128/AAC.00451-12] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
34 Shahid I, ALMalki WH, Hafeez MH, Hassan S. Hepatitis C virus infection treatment: An era of game changer direct acting antivirals and novel treatment strategies. Crit Rev Microbiol. 2014;1-13. [PMID: 25373616 DOI: 10.3109/1040841x.2014.970123] [Cited by in Crossref: 23] [Cited by in F6Publishing: 12] [Article Influence: 2.9] [Reference Citation Analysis]
35 Mathew S, Faheem M, Archunan G, Ilyas M, Begum N, Jahangir S, Qadri I, Qahtani MA, Mathew S. In silico studies of medicinal compounds against hepatitis C capsid protein from north India. Bioinform Biol Insights. 2014;8:159-168. [PMID: 25002815 DOI: 10.4137/bbi.s15211] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
36 Hofmann WP, Mauss S, Lutz T, Schober A, Böker K, Moog G, Baumgarten A, Pfeiffer-Vornkahl H, Alshuth U, Hüppe D, Wedemeyer H, Manns MP, Schott E. Benefit of Treatment Individualization in Patients with Chronic Hepatitis C Receiving Peginterferon Alfa-2a and Ribavirin in a Large Noninterventional Cohort Study. PLoS One 2015;10:e0134839. [PMID: 26230998 DOI: 10.1371/journal.pone.0134839] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
37 Cuypers L, Snoeck J, Kerremans L, Libin P, Crabbé R, Van Dooren S, Vuagniaux G, Vandamme AM. HCV1b genome evolution under selective pressure of the cyclophilin inhibitor alisporivir during the DEB-025-HCV-203 phase II clinical trial. Infect Genet Evol 2016;44:169-81. [PMID: 27374748 DOI: 10.1016/j.meegid.2016.06.050] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
38 Abad-fernández M, Dronda F, Moreno A, Casado JL, Pérez-elías M, Quereda C, Moreno S, Vallejo A. Brief Report: Reduced Cell-Associated HTLV-2 DNA in Antiretroviral Treated HIV-1–HCV-Coinfected Patients Who Either Received Interferon-α/Ribavirin-Based Hepatitis C Therapy or Had Spontaneous HCV RNA Clearance. JAIDS Journal of Acquired Immune Deficiency Syndromes 2015;69:286-90. [DOI: 10.1097/qai.0000000000000608] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
39 Arnaud C, Trépo C, Petit M. Predictors of the therapeutic response in hepatitis C. A 2013 update. Clinics and Research in Hepatology and Gastroenterology 2014;38:12-7. [DOI: 10.1016/j.clinre.2013.08.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
40 Madian AG, Baker Jones R. Variable Drug Response: Genetic Evaluation. In: John Wiley & Sons Ltd, editor. eLS. Chichester: John Wiley & Sons, Ltd; 2001. [DOI: 10.1002/9780470015902.a0006001.pub2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
41 Meguellati A, Ahmed-belkacem A, Yi W, Haudecoeur R, Crouillère M, Brillet R, Pawlotsky J, Boumendjel A, Peuchmaur M. B-ring modified aurones as promising allosteric inhibitors of hepatitis C virus RNA-dependent RNA polymerase. European Journal of Medicinal Chemistry 2014;80:579-92. [DOI: 10.1016/j.ejmech.2014.04.005] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
42 Shih W, Fang C, Chen P. Anti-Viral Treatment and Cancer Control. In: Chang MH, Jeang K, editors. Viruses and Human Cancer. Berlin: Springer Berlin Heidelberg; 2014. pp. 269-90. [DOI: 10.1007/978-3-642-38965-8_14] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
43 Robaeys G, Grebely J, Mauss S, Bruggmann P, Moussalli J, De Gottardi A, Swan T, Arain A, Kautz A, Stöver H. Recommendations for the management of hepatitis C virus infection among people who inject drugs. Clin Infect Dis. 2013;57 Suppl 2:S129-S137. [PMID: 23884061 DOI: 10.1093/cid/cit302] [Cited by in Crossref: 79] [Cited by in F6Publishing: 80] [Article Influence: 9.9] [Reference Citation Analysis]
44 Vassilopoulos D, Calabrese LH. Management of rheumatic disease with comorbid HBV or HCV infection. Nat Rev Rheumatol 2012;8:348-57. [DOI: 10.1038/nrrheum.2012.63] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 4.4] [Reference Citation Analysis]
45 Corchado S, López-Cortés LF, Rivero-Juárez A, Torres-Cornejo A, Rivero A, Márquez-Coello M, Girón-González JA. Liver fibrosis, host genetic and hepatitis C virus related parameters as predictive factors of response to therapy against hepatitis C virus in HIV/HCV coinfected patients. PLoS One. 2014;9:e101760. [PMID: 25013899 DOI: 10.1371/journal.pone.0101760] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
46 Reynolds JM, Paciga SA, Sanders FA, Hyde CL, Loomis AK, Johnston GI. Sequence analysis of the IL28A/IL28B inverted gene duplication that contains polymorphisms associated with treatment response in hepatitis C patients. PLoS One 2012;7:e29983. [PMID: 22253847 DOI: 10.1371/journal.pone.0029983] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
47 Hansen N, Obel N, Christensen PB, Kjær M, Laursen AL, Krarup HB, Møller A, Schlichting P, Bukh J, Weis N; Danish Database for Hepatitis B and C (DANHEP)- group. Effectiveness of treatment with pegylated interferon and ribavirin in an unselected population of patients with chronic hepatitis C: a Danish nationwide cohort study. BMC Infect Dis 2011;11:177. [PMID: 21693019 DOI: 10.1186/1471-2334-11-177] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
48 Moriishi K. The potential of signal peptide peptidase as a therapeutic target for hepatitis C. Expert Opinion on Therapeutic Targets 2017;21:827-36. [DOI: 10.1080/14728222.2017.1369959] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
49 Rallón NI, Pineda JA, Soriano V, Neukam K, Vispo E, Rivero A, Labarga P, Caruz A, Restrepo C, Camacho A, Barreiro P, Benito JM. Differences in Virological Response to Peginterferon-α Plus Ribavirin in HIV-Positive Patients Coinfected With HCV Subtypes 1a or 1b. JAIDS Journal of Acquired Immune Deficiency Syndromes 2012;60:117-23. [DOI: 10.1097/qai.0b013e31824f5506] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 0.9] [Reference Citation Analysis]
50 Kawaguchi-suzuki M, Frye RF. The Role of Pharmacogenetics in the Treatment of Chronic Hepatitis C Infection. Pharmacotherapy 2014;34:185-201. [DOI: 10.1002/phar.1349] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
51 McGivern DR, Masaki T, Williford S, Ingravallo P, Feng Z, Lahser F, Asante-Appiah E, Neddermann P, De Francesco R, Howe AY. Kinetic analyses reveal potent and early blockade of hepatitis C virus assembly by NS5A inhibitors. Gastroenterology. 2014;147:453-462.e7. [PMID: 24768676 DOI: 10.1053/j.gastro.2014.04.021] [Cited by in Crossref: 85] [Cited by in F6Publishing: 86] [Article Influence: 10.6] [Reference Citation Analysis]
52 Indolfi G, Azzari C, Resti M. Polymorphisms in the IFNL3/IL28B gene and hepatitis C: From adults to children. World J Gastroenterol 2014; 20(28): 9245-9252 [PMID: 25071317 DOI: 10.3748/wjg.v20.i28.9245] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
53 Callendret B, Walker CM. Will there be a vaccine to protect against the hepatitis C virus? Gastroenterology 2012;142:1384-7. [PMID: 22537447 DOI: 10.1053/j.gastro.2012.02.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
54 Chang MH, Gordon LA, Fung HB. Boceprevir: a protease inhibitor for the treatment of hepatitis C. Clin Ther. 2012;34:2021-2038. [PMID: 22975763 DOI: 10.1016/j.clinthera.2012.08.009] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
55 Molina-Jimenez F, Benedicto I, Dao Thi VL, Gondar V, Lavillette D, Marin JJ, Briz O, Moreno-Otero R, Aldabe R, Baumert TF, Cosset FL, Lopez-Cabrera M, Majano PL. Matrigel-embedded 3D culture of Huh-7 cells as a hepatocyte-like polarized system to study hepatitis C virus cycle. Virology 2012;425:31-9. [PMID: 22280897 DOI: 10.1016/j.virol.2011.12.021] [Cited by in Crossref: 59] [Cited by in F6Publishing: 55] [Article Influence: 5.9] [Reference Citation Analysis]
56 Aiken T, Garber A, Thomas D, Hamon N, Lopez R, Konjeti R, McCullough A, Zein N, Fung J, Askar M, John BV. Donor IFNL4 Genotype Is Associated with Early Post-Transplant Fibrosis in Recipients with Hepatitis C. PLoS One 2016;11:e0166998. [PMID: 27875564 DOI: 10.1371/journal.pone.0166998] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
57 Gallego P, Rojas Á, Falcón G, Carbonero P, García-Lozano MR, Gil A, Grande L, Cremades O, Romero-Gómez M, Bautista JD, Del Campo JA. Water-soluble extracts from edible mushrooms (Agaricus bisporus) as inhibitors of hepatitis C viral replication. Food Funct 2019;10:3758-67. [PMID: 31179460 DOI: 10.1039/c9fo00733d] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
58 Loftis JM, Patterson AL, Wilhelm CJ, McNett H, Morasco BJ, Huckans M, Morgan T, Saperstein S, Asghar A, Hauser P. Vulnerability to somatic symptoms of depression during interferon-alpha therapy for hepatitis C: a 16-week prospective study. J Psychosom Res. 2013;74:57-63. [PMID: 23272989 DOI: 10.1016/j.jpsychores.2012.10.012] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 3.3] [Reference Citation Analysis]
59 Schiering N, D'Arcy A, Villard F, Simic O, Kamke M, Monnet G, Hassiepen U, Svergun DI, Pulfer R, Eder J, Raman P, Bodendorf U. A macrocyclic HCV NS3/4A protease inhibitor interacts with protease and helicase residues in the complex with its full-length target. Proc Natl Acad Sci U S A 2011;108:21052-6. [PMID: 22160684 DOI: 10.1073/pnas.1110534108] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 3.3] [Reference Citation Analysis]
60 Nitta S, Sakamoto N, Nakagawa M, Kakinuma S, Mishima K, Kusano-Kitazume A, Kiyohashi K, Murakawa M, Nishimura-Sakurai Y, Azuma S. Hepatitis C virus NS4B protein targets STING and abrogates RIG-I-mediated type I interferon-dependent innate immunity. Hepatology. 2013;57:46-58. [PMID: 22911572 DOI: 10.1002/hep.26017] [Cited by in Crossref: 94] [Cited by in F6Publishing: 92] [Article Influence: 10.4] [Reference Citation Analysis]
61 Venkatesan A, Prabhu Dass J F. Review on chemogenomic approaches towards hepatitis C viral targets. J Cell Biochem 2019;120:12167-81. [PMID: 30887580 DOI: 10.1002/jcb.28581] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
62 Hou W, Qiao K, Huo Z, Du Y, Wang C, Syn WK. Association of IFNL3 rs12979860 polymorphism with HCV-related hepatocellular carcinoma susceptibility in a Chinese population. Clin Exp Gastroenterol 2019;12:433-9. [PMID: 31807049 DOI: 10.2147/CEG.S206194] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
63 Ford N, Kirby C, Singh K, Mills EJ, Cooke G, Kamarulzaman A, duCros P. Chronic hepatitis C treatment outcomes in low- and middle-income countries: a systematic review and meta-analysis. Bull World Health Organ. 2012;90:540-550. [PMID: 22807600 DOI: 10.2471/blt.11.097147] [Cited by in Crossref: 41] [Cited by in F6Publishing: 21] [Article Influence: 4.1] [Reference Citation Analysis]
64 Gonzalez-aldaco K, Panduro A, Rebello Pinho JR, Martinez-lopez E, Gleyzer K, Fierro NA, Roman S. High Prevalence of ITPA Alleles Associated with Ribavirin-Induced Hemolytic Anemia Among Mexican Population. Annals of Hepatology 2017;16:221-9. [DOI: 10.5604/16652681.1231582] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
65 Panigrahi R, Hazari S, Chandra S, Chandra PK, Datta S, Kurt R, Cameron CE, Huang Z, Zhang H, Garry RF, Balart LA, Dash S. Interferon and ribavirin combination treatment synergistically inhibit HCV internal ribosome entry site mediated translation at the level of polyribosome formation. PLoS One 2013;8:e72791. [PMID: 24009705 DOI: 10.1371/journal.pone.0072791] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
66 Read SA, Douglas MW. Virus induced inflammation and cancer development. Cancer Lett 2014;345:174-81. [PMID: 23941825 DOI: 10.1016/j.canlet.2013.07.030] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 4.1] [Reference Citation Analysis]
67 Mi Y, Gao YT, Jiao XL, Guo H, Liu T, Jing L, Shi WX, Du Z. The role of interleukin-28b gene polymorphisms in chinese patients with chronic hepatitis C treated with pegylated interferon and ribavirin. Hepat Mon 2014;14:e18793. [PMID: 25337144 DOI: 10.5812/hepatmon.18793] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
68 Fofana I, Fafi-Kremer S, Carolla P, Fauvelle C, Zahid MN, Turek M, Heydmann L, Cury K, Hayer J, Combet C, Cosset FL, Pietschmann T, Hiet MS, Bartenschlager R, Habersetzer F, Doffoël M, Keck ZY, Foung SKH, Zeisel MB, Stoll-Keller F, Baumert TF. Mutations that alter use of hepatitis C virus cell entry factors mediate escape from neutralizing antibodies. Gastroenterology 2012;143:223-233.e9. [PMID: 22503792 DOI: 10.1053/j.gastro.2012.04.006] [Cited by in Crossref: 59] [Cited by in F6Publishing: 60] [Article Influence: 5.9] [Reference Citation Analysis]
69 Cooper CL, Druyts E, Thorlund K, Nachega JB, El Khoury AC, O’Regan C, Mills EJ. Boceprevir and telaprevir for the treatment of chronic hepatitis C genotype 1 infection: an indirect comparison meta-analysis. Ther Clin Risk Manag. 2012;8:105-130. [PMID: 22442631 DOI: 10.2147/tcrm.s29830] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.1] [Reference Citation Analysis]
70 Lloyd AR, Clegg J, Lange J, Stevenson A, Post JJ, Lloyd D, Rudge G, Boonwaat L, Forrest G, Douglas J, Monkley D. Safety and effectiveness of a nurse-led outreach program for assessment and treatment of chronic hepatitis C in the custodial setting. Clin Infect Dis 2013;56:1078-84. [PMID: 23362288 DOI: 10.1093/cid/cis1202] [Cited by in Crossref: 93] [Cited by in F6Publishing: 88] [Article Influence: 10.3] [Reference Citation Analysis]
71 Grebely J, Bilodeau M, Feld JJ, Bruneau J, Fischer B, Raven JF, Roberts E, Choucha N, Myers RP, Sagan SM, Wilson JA, Bialystok F, Tyrrell DL, Houghton M, Krajden M; National CIHR Research Training Program in Hepatitis C. The Second Canadian Symposium on hepatitis C virus: a call to action. Can J Gastroenterol 2013;27:627-32. [PMID: 24199209 DOI: 10.1155/2013/242405] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
72 Cuypers L, Li G, Libin P, Piampongsant S, Vandamme AM, Theys K. Genetic Diversity and Selective Pressure in Hepatitis C Virus Genotypes 1-6: Significance for Direct-Acting Antiviral Treatment and Drug Resistance. Viruses 2015;7:5018-39. [PMID: 26389941 DOI: 10.3390/v7092857] [Cited by in Crossref: 48] [Cited by in F6Publishing: 45] [Article Influence: 6.9] [Reference Citation Analysis]
73 Rivero-Juarez A, Gonzalez R, Camacho A, Manzanares-Martin B, Caruz A, Martinez-Peinado A, Torre-Cisneros J, Pineda JA, Peña J, Rivero A. Natural killer KIR3DS1 is closely associated with HCV viral clearance and sustained virological response in HIV/HCV patients. PLoS One. 2013;8:e61992. [PMID: 23613999 DOI: 10.1371/journal.pone.0061992] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 2.6] [Reference Citation Analysis]
74 Yamashita A, Salam KA, Furuta A, Matsuda Y, Fujita O, Tani H, Fujita Y, Fujimoto Y, Ikeda M, Kato N, Sakamoto N, Maekawa S, Enomoto N, Nakakoshi M, Tsubuki M, Sekiguchi Y, Tsuneda S, Akimitsu N, Noda N, Tanaka J, Moriishi K. Inhibition of hepatitis C virus replication and viral helicase by ethyl acetate extract of the marine feather star Alloeocomatella polycladia. Mar Drugs 2012;10:744-61. [PMID: 22690141 DOI: 10.3390/md10040744] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
75 Shen H, Yamashita A, Nakakoshi M, Yokoe H, Sudo M, Kasai H, Tanaka T, Fujimoto Y, Ikeda M, Kato N, Sakamoto N, Shindo H, Maekawa S, Enomoto N, Tsubuki M, Moriishi K. Inhibitory effects of caffeic acid phenethyl ester derivatives on replication of hepatitis C virus. PLoS One 2013;8:e82299. [PMID: 24358168 DOI: 10.1371/journal.pone.0082299] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.2] [Reference Citation Analysis]
76 Dultz G, Seelhof M, Herrmann E, Welker MW, Friedrich-Rust M, Teuber G, Kronenberger B, von Wagner M, Vermehren J, Sarrazin C. Baseline MELD score predicts hepatic decompensation during antiviral therapy in patients with chronic hepatitis C and advanced cirrhosis. PLoS One. 2013;8:e71262. [PMID: 23936497 DOI: 10.1371/journal.pone.0071262] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
77 Christensen PB, Hay G, Jepsen P, Omland LH, Just SA, Krarup HB, Weis N, Obel N, Cowan S. Hepatitis C prevalence in Denmark -an estimate based on multiple national registers. BMC Infect Dis. 2012;12:178. [PMID: 22866925 DOI: 10.1186/1471-2334-12-178] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 4.3] [Reference Citation Analysis]
78 Horner SM. Activation and Evasion of Antiviral Innate Immunity by Hepatitis C Virus. J Mol Biol. 2014;426:1198-1209. [PMID: 24184198 DOI: 10.1016/j.jmb.2013.10.032] [Cited by in Crossref: 50] [Cited by in F6Publishing: 46] [Article Influence: 5.6] [Reference Citation Analysis]
79 Zeng Q, Nair AG, Rosenblum SB, Huang H, Lesburg CA, Jiang Y, Selyutin O, Chan T, Bennett F, Chen KX, Venkatraman S, Sannigrahi M, Velazquez F, Duca JS, Gavalas S, Huang Y, Pu H, Wang L, Pinto P, Vibulbhan B, Agrawal S, Ferrari E, Jiang C, Li C, Hesk D, Gesell J, Sorota S, Shih N, Njoroge FG, Kozlowski JA. Discovery of an irreversible HCV NS5B polymerase inhibitor. Bioorganic & Medicinal Chemistry Letters 2013;23:6585-7. [DOI: 10.1016/j.bmcl.2013.10.060] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
80 Jin Z, Leveque V, Ma H, Johnson KA, Klumpp K. NTP-mediated nucleotide excision activity of hepatitis C virus RNA-dependent RNA polymerase. Proc Natl Acad Sci U S A 2013;110:E348-57. [PMID: 23307808 DOI: 10.1073/pnas.1214924110] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 3.4] [Reference Citation Analysis]
81 Wadood A, Riaz M, Jamal SB, Shah M, Lodhi MA. Molecular docking study of P4-Benzoxaborolesubstituted ligands as inhibitors of HCV NS3/4A protease. Bioinformation 2013;9:309-14. [PMID: 23559750 DOI: 10.6026/97320630009309] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
82 Shih WL, Fang CT, Chen PJ. Chapter XX Antiviral Treatment and Cancer Control. Recent Results Cancer Res 2021;217:325-54. [PMID: 33200371 DOI: 10.1007/978-3-030-57362-1_13] [Reference Citation Analysis]
83 Fischer J, Böhm S, Scholz M, Müller T, Witt H, George J, Sarrazin C, Susser S, Schott E, Suppiah V, Booth DR, Stewart GJ, van Bömmel F, Brodzinski A, Fülöp B, Migaud P, Berg T. Combined effects of different interleukin-28B gene variants on the outcome of dual combination therapy in chronic hepatitis C virus type 1 infection. Hepatology 2012;55:1700-10. [DOI: 10.1002/hep.25582] [Cited by in Crossref: 64] [Cited by in F6Publishing: 65] [Article Influence: 6.4] [Reference Citation Analysis]
84 Chang CC, Crane M, Zhou J, Mina M, Post JJ, Cameron BA, Lloyd AR, Jaworowski A, French MA, Lewin SR. HIV and co-infections. Immunol Rev 2013;254:114-42. [PMID: 23772618 DOI: 10.1111/imr.12063] [Cited by in Crossref: 75] [Cited by in F6Publishing: 61] [Article Influence: 9.4] [Reference Citation Analysis]
85 Garbuglia AR, Lionetti R, Lapa D, Taibi C, Visco-Comandini U, Montalbano M, D'Offizi G, Castiglione F, Capobianchi MR, Paci P. The clinical significance of HCV core antigen detection during Telaprevir/Peg-Interferon/Ribavirin therapy in patients with HCV 1 genotype infection. J Clin Virol 2015;69:68-73. [PMID: 26209382 DOI: 10.1016/j.jcv.2015.06.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
86 Moriishi K, Matsuura Y. Exploitation of lipid components by viral and host proteins for hepatitis C virus infection. Front Microbiol. 2012;3:54. [PMID: 22347882 DOI: 10.3389/fmicb.2012.00054] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 2.5] [Reference Citation Analysis]
87 Thorlund K, Druyts E, El Khoury AC, Mills EJ. Budget impact analysis of boceprevir and telaprevir for the treatment of hepatitis C genotype 1 infection. Clinicoecon Outcomes Res 2012;4:349-59. [PMID: 23180971 DOI: 10.2147/CEOR.S37205] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
88 Rivero-Juárez A, Morgaz J, Camacho A, Muñoz-Rascón P, Dominguez JM, Sánchez-Céspedes R, Torre-Cisneros J, Rivero A. Liver stiffness using transient elastography is applicable to canines for hepatic disease models. PLoS One 2012;7:e41557. [PMID: 22911813 DOI: 10.1371/journal.pone.0041557] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
89 Qin H, Li H, Zhou X, Feng F, Shen Y, Tan H, Ye F, Xie Y. Safety of telaprevir for chronic hepatitis C virus infection: a meta-analysis of randomized controlled trials. Clin Drug Investig. 2012;32:665-672. [PMID: 22889114 DOI: 10.1007/bf03261920] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
90 Calland N, Dubuisson J, Rouillé Y, Séron K. Hepatitis C virus and natural compounds: a new antiviral approach? Viruses 2012;4:2197-217. [PMID: 23202460 DOI: 10.3390/v4102197] [Cited by in Crossref: 77] [Cited by in F6Publishing: 67] [Article Influence: 7.7] [Reference Citation Analysis]
91 Jaspe RC, Sulbarán YF, Sulbarán MZ, Loureiro CL, Rangel HR, Pujol FH. Prevalence of amino acid mutations in hepatitis C virus core and NS5B regions among Venezuelan viral isolates and comparison with worldwide isolates. Virol J 2012;9:214. [PMID: 22995142 DOI: 10.1186/1743-422X-9-214] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
92 Kohli V, Singhal A, Elliott L, Jalil S. Antiviral therapy for recurrent hepatitis C reduces recurrence of hepatocellular carcinoma following liver transplantation. Transpl Int. 2012;25:192-200. [PMID: 22151471 DOI: 10.1111/j.1432-2277.2011.01396.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
93 Beq S, Rozlan S, Pelletier S, Willems B, Bruneau J, Lelievre JD, Levy Y, Shoukry NH, Cheynier R. Altered thymic function during interferon therapy in HCV-infected patients. PLoS One 2012;7:e34326. [PMID: 22529911 DOI: 10.1371/journal.pone.0034326] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
94 Fujimoto Y, Salam KA, Furuta A, Matsuda Y, Fujita O, Tani H, Ikeda M, Kato N, Sakamoto N, Maekawa S, Enomoto N, de Voogd NJ, Nakakoshi M, Tsubuki M, Sekiguchi Y, Tsuneda S, Akimitsu N, Noda N, Yamashita A, Tanaka J, Moriishi K. Inhibition of both protease and helicase activities of hepatitis C virus NS3 by an ethyl acetate extract of marine sponge Amphimedon sp. PLoS One 2012;7:e48685. [PMID: 23144928 DOI: 10.1371/journal.pone.0048685] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]